+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Circulating Tumor DNA Diagnostics Market - Global Forecast 2026-2032- Product Image
Circulating Tumor DNA Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Circulating Tumor DNA Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6278956
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Circulating Tumor DNA Diagnostics: Executive Summary

Circulating tumor DNA (ctDNA) diagnostics analyze tumor-derived DNA fragments found in blood and other liquid-biopsy samples. The field is advancing from research use toward clinically validated applications in treatment selection, residual-disease assessment, recurrence monitoring, and disease surveillance. Adoption depends on analytical sensitivity, clinical evidence, reimbursement, laboratory capability, and integration into oncology workflows.

Clinical Translation Is Reshaping ctDNA Diagnostics

The landscape is shifting from proof-of-concept testing toward defined clinical-use pathways. Improvements in sequencing, error suppression, molecular barcoding, and bioinformatics are helping laboratories detect low-frequency variants, while prospective studies are increasingly evaluating whether ctDNA results can guide treatment decisions. Key barriers remain, including biological shedding differences across tumor types, false-negative results at low disease burden, pre-analytical variability, and the need for standardized interpretation and reporting.

Artificial Intelligence Strengthens Signal Detection and Interpretation

Artificial intelligence and machine learning are contributing to ctDNA workflows by supporting variant classification, background-error modeling, fragment-pattern analysis, multimodal data integration, and patient-risk stratification. These tools may improve analytical consistency and help extract information from sparse molecular signals, but their clinical value depends on representative training data, transparent validation, external replication, and safeguards against algorithmic bias. Human oversight and clinically interpretable reporting remain essential.

Regional Insights: Adoption Reflects Evidence, Infrastructure, and Regulation

North America is characterized by advanced oncology infrastructure, active clinical research, and growing attention to molecular residual disease and therapy selection. Europe combines strong translational research with rigorous evidence and health-technology assessment requirements, while the European Union faces variation in reimbursement and implementation across member states. Asia-Pacific includes highly capable diagnostic systems alongside substantial differences in access, laboratory standardization, and regulatory maturity. Latin America is expanding specialized molecular testing but remains sensitive to affordability, centralization, and uneven reimbursement. The Middle East is developing precision-oncology capacity through tertiary centers and national health initiatives, while Africa’s progress is shaped by limited laboratory access, workforce constraints, and the need for scalable sample logistics.

Group Insights: Alliances Influence Standards and Access

ASEAN presents a mixed environment in which urban specialist centers may adopt advanced liquid-biopsy testing faster than broader health systems. BRICS economies combine substantial scientific and clinical capacity with differing regulatory pathways, reimbursement conditions, and domestic laboratory capabilities. The European Union emphasizes evidence generation, data governance, and coordinated but nationally implemented healthcare policy. G7 countries generally benefit from mature research ecosystems and sophisticated oncology services, although equitable access and cost-effectiveness remain important considerations. GCC members are investing in centralized precision-medicine infrastructure, while NATO countries reflect diverse healthcare systems but share strong interest in resilient diagnostics, data exchange, and biomedical innovation.

Country Insights: National Capacity Determines Clinical Integration

Australia combines strong clinical research with geographic access challenges. Brazil and Mexico are expanding molecular oncology services while confronting regional disparities and reimbursement constraints. Canada and the United States have advanced precision-oncology ecosystems, with implementation influenced by evidence standards, payer policy, and laboratory regulation. China, Japan, and South Korea possess substantial sequencing and hospital capacity, although regulatory processes and clinical adoption pathways differ. India is developing broad molecular-testing capability alongside pronounced variation between metropolitan and regional care. France, Germany, Italy, Spain, and the United Kingdom have established cancer systems, but adoption is shaped by national evidence assessment, procurement, and reimbursement frameworks. Russia has scientific and clinical resources but faces constraints related to access, supply chains, and international collaboration.

Action Priorities for Leaders Building Reliable ctDNA Programs

Industry leaders should define a specific clinical question before selecting an assay, then validate performance in the intended tumor types, specimen conditions, and care settings. They should invest in standardized collection and processing protocols, orthogonal confirmation where appropriate, transparent quality metrics, and clinician-friendly reports that distinguish actionable findings from investigational signals. Partnerships with hospitals and public laboratories can strengthen prospective evidence, while health-economic studies can support reimbursement discussions. Organizations should also establish governance for artificial intelligence, protect genomic data, monitor post-deployment performance, and design access models suited to regional infrastructure and patient needs.

Research Methodology: Evidence-Based Assessment of the Diagnostic Landscape

This executive summary uses a structured assessment of ctDNA diagnostic applications, enabling technologies, clinical validation, healthcare infrastructure, regulation, and implementation conditions. Evidence should be triangulated across peer-reviewed clinical studies, prospective trials, regulatory and reimbursement materials, professional guidelines, public-health data, and laboratory standards. Findings are interpreted comparatively across the specified regions, groups, and countries, with attention to assay performance, tumor biology, workflow requirements, and healthcare-system readiness. Because clinical evidence and policy environments evolve, conclusions should be revisited as validation studies, guidelines, and regulatory decisions change.

Conclusion: Clinical Utility Will Define the Next Stage of ctDNA Adoption

ctDNA diagnostics are becoming an important component of precision oncology, but technological capability alone will not determine sustained adoption. The decisive factors will be reproducible analytical performance, clinically meaningful outcomes, fit with treatment pathways, responsible use of artificial intelligence, and equitable access. Leaders that align assay development with validated clinical utility, robust quality systems, and region-specific implementation strategies will be best positioned to translate liquid-biopsy advances into dependable patient care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Circulating Tumor DNA Diagnostics Market, by Product Type
7.1. Introduction
7.2. Instruments
7.2.1. Automation Systems
7.2.2. Digital PCR Instruments
7.2.3. Sequencers
7.3. Kits
7.3.1. Assay Panels
7.3.2. Controls And Reagents
7.3.3. Extraction Kits
7.3.4. Library Preparation Kits
7.4. Services
7.4.1. Bioinformatics Services
7.4.2. Testing Services
7.5. Software
7.5.1. Analysis Software
7.5.2. Data Management Platforms
8. Circulating Tumor DNA Diagnostics Market, by Technology
8.1. Introduction
8.2. Next Generation Sequencing
8.2.1. Amplicon Sequencing
8.2.2. Hybrid Capture
8.2.3. Targeted Ngs
8.2.4. Whole Exome Sequencing
8.2.5. Whole Genome Sequencing
8.3. Pcr Based
8.3.1. Digital PCR
8.3.2. Real Time PCR
9. Circulating Tumor DNA Diagnostics Market, by Sample Type
9.1. Introduction
9.2. Plasma
9.3. Serum
9.4. Urine
9.5. Whole Blood
10. Circulating Tumor DNA Diagnostics Market, by Application
10.1. Introduction
10.2. Early Detection
10.2.1. High Risk Screening
10.2.2. Population Screening
10.3. Minimal Residual Disease Monitoring
10.4. Prognostic Assessment
10.5. Recurrence Monitoring
10.6. Therapy Response Monitoring
10.7. Treatment Selection
10.7.1. Biomarker Guided Therapy
10.7.2. Companion Diagnostics
11. Circulating Tumor DNA Diagnostics Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Central Laboratories
11.2.2. Reference Laboratories
11.3. Hospitals
11.3.1. Oncology Departments
11.3.2. Pathology Labs
11.4. Oncology Clinics
11.5. Pharmaceutical Companies
11.6. Research Laboratories
12. Circulating Tumor DNA Diagnostics Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Circulating Tumor DNA Diagnostics Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Circulating Tumor DNA Diagnostics Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bio-Rad Laboratories, Inc.
16.2. Exact Sciences Corporation
16.3. F. Hoffmann-La Roche Ltd
16.4. Foundation Medicine, Inc.
16.5. GRAIL, Inc.
16.6. Guardant Health, Inc.
16.7. Illumina, Inc.
16.8. Lucence Health Pte. Ltd.
16.9. Myriad Genetics, Inc.
16.10. Natera, Inc.
16.11. NeoGenomics Laboratories, Inc.
16.12. Personal Genome Diagnostics, Inc.
16.13. Predicine, Inc.
16.14. QIAGEN N.V.
16.15. Sysmex Inostics GmbH
16.16. Thermo Fisher Scientific Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Circulating Tumor DNA Diagnostics Market, Years Considered for the Study
FIGURE 2. Global Circulating Tumor DNA Diagnostics Market, Research Design
FIGURE 3. Global Circulating Tumor DNA Diagnostics Market, Research Framework
FIGURE 4. Global Circulating Tumor DNA Diagnostics Market, Data Triangulation
FIGURE 5. Global Circulating Tumor DNA Diagnostics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Circulating Tumor DNA Diagnostics Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Circulating Tumor DNA Diagnostics Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2025 vs 2032 (%)
FIGURE 11. Global Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Circulating Tumor DNA Diagnostics Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Circulating Tumor DNA Diagnostics Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Circulating Tumor DNA Diagnostics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Circulating Tumor DNA Diagnostics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Circulating Tumor DNA Diagnostics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Circulating Tumor DNA Diagnostics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Circulating Tumor DNA Diagnostics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Circulating Tumor DNA Diagnostics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Circulating Tumor DNA Diagnostics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Circulating Tumor DNA Diagnostics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Circulating Tumor DNA Diagnostics Market Segmentation & Coverage
TABLE 2. Global Circulating Tumor DNA Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Automation Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Automation Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Automation Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Digital PCR Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Digital PCR Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Digital PCR Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Sequencers Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Sequencers Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Sequencers Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Assay Panels Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Assay Panels Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Assay Panels Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Controls And Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Controls And Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Controls And Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Extraction Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Extraction Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Extraction Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Library Preparation Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Library Preparation Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Library Preparation Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Bioinformatics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Bioinformatics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Bioinformatics Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Testing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Testing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Testing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Analysis Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Analysis Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Analysis Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Data Management Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Data Management Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Data Management Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 50. Global Next Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Next Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Next Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Amplicon Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Amplicon Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Amplicon Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Hybrid Capture Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hybrid Capture Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hybrid Capture Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Targeted Ngs Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Targeted Ngs Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Targeted Ngs Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Whole Exome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Whole Exome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Whole Exome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Whole Genome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Whole Genome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Whole Genome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Pcr Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Pcr Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Pcr Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Digital PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Digital PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Digital PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Real Time PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Real Time PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Real Time PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 78. Global Plasma Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Plasma Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Plasma Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Serum Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Serum Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Serum Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Urine Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Urine Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Urine Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Whole Blood Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Whole Blood Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Whole Blood Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 91. Global Early Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Early Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Early Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global High Risk Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global High Risk Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global High Risk Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Population Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Population Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Population Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Minimal Residual Disease Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Minimal Residual Disease Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Minimal Residual Disease Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Prognostic Assessment Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Prognostic Assessment Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Prognostic Assessment Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Recurrence Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Recurrence Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Recurrence Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Therapy Response Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Therapy Response Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Therapy Response Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Treatment Selection Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Treatment Selection Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Treatment Selection Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Biomarker Guided Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Biomarker Guided Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Biomarker Guided Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Companion Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Companion Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Companion Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Central Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Central Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Central Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Reference Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Reference Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Reference Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Oncology Departments Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Oncology Departments Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Oncology Departments Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Pathology Labs Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Pathology Labs Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Pathology Labs Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Research Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Research Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Research Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 166. North America Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. North America Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. North America Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 169. North America Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 170. North America Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 171. North America Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 172. North America Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 173. North America Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 174. North America Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 175. North America Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 176. North America Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 177. North America Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 178. North America Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 179. North America Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. North America Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 181. North America Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 182. Latin America Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Latin America Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. Latin America Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 185. Latin America Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 186. Latin America Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 187. Latin America Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 188. Latin America Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 189. Latin America Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 190. Latin America Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 191. Latin America Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 192. Latin America Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 193. Latin America Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 194. Latin America Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 195. Latin America Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Latin America Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 197. Latin America Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 198. Europe Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Europe Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. Europe Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 201. Europe Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 202. Europe Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 203. Europe Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 204. Europe Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 205. Europe Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 206. Europe Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 207. Europe Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 208. Europe Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 209. Europe Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 210. Europe Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 211. Europe Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Europe Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 213. Europe Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 214. Middle East Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. Middle East Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 216. Middle East Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 217. Middle East Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 218. Middle East Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 219. Middle East Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 220. Middle East Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 221. Middle East Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 222. Middle East Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 223. Middle East Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 224. Middle East Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 225. Middle East Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 226. Middle East Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 227. Middle East Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. Middle East Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 229. Middle East Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 230. Africa Circulating Tumor DNA Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 231. Africa Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 232. Africa Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 233. Africa Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 234. Africa Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 235. Africa Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 236. Africa Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 237. Africa Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 238. Africa Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 239. Africa Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 240. Africa Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 241. Africa Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 242. Africa Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 243. Africa Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Africa Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 245. Africa Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 246. Global Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 247. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 248. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 250. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 251. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 252. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 253. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 254. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 255. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 256. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 257. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 258. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 259. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 260. ASEAN Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 262. ASEAN Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 263. GCC Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 264. GCC Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 265. GCC Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 266. GCC Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 267. GCC Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 268. GCC Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 269. GCC Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 270. GCC Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 271. GCC Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 272. GCC Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 273. GCC Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 274. GCC Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 275. GCC Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 276. GCC Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. GCC Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 278. GCC Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 279. European Union Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 280. European Union Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 281. European Union Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 282. European Union Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 283. European Union Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 284. European Union Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 285. European Union Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 286. European Union Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 287. European Union Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 288. European Union Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 289. European Union Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 290. European Union Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 291. European Union Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 292. European Union Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. European Union Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 294. European Union Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 295. BRICS Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. BRICS Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. BRICS Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 298. BRICS Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 299. BRICS Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 300. BRICS Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 301. BRICS Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 302. BRICS Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 303. BRICS Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 304. BRICS Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 305. BRICS Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 306. BRICS Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 307. BRICS Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 308. BRICS Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 309. BRICS Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 310. BRICS Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 311. G7 Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 312. G7 Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 313. G7 Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 314. G7 Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 315. G7 Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 316. G7 Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 317. G7 Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 318. G7 Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 319. G7 Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 320. G7 Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 321. G7 Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (USD Million)
TABLE 322. G7 Circulating Tumor DNA Diagnostics Market Size, by Early Detection, 2017-2032 (USD Million)
TABLE 323. G7 Circulating Tumor DNA Diagnostics Market Size, by Treatment Selection, 2017-2032 (USD Million)
TABLE 324. G7 Circulating Tumor DNA Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 325. G7 Circulating Tumor DNA Diagnostics Market Size, by Diagnostic Laboratories, 2017-2032 (USD Million)
TABLE 326. G7 Circulating Tumor DNA Diagnostics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 327. NATO Circulating Tumor DNA Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 328. NATO Circulating Tumor DNA Diagnostics Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 329. NATO Circulating Tumor DNA Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 330. NATO Circulating Tumor DNA Diagnostics Market Size, by Kits, 2017-2032 (USD Million)
TABLE 331. NATO Circulating Tumor DNA Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 332. NATO Circulating Tumor DNA Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 333. NATO Circulating Tumor DNA Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 334. NATO Circulating Tumor DNA Diagnostics Market Size, by Next Generation Sequencing, 2017-2032 (USD Million)
TABLE 335. NATO Circulating Tumor DNA Diagnostics Market Size, by Pcr Based, 2017-2032 (USD Million)
TABLE 336. NATO Circulating Tumor DNA Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 337. NATO Circulating Tumor DNA Diagnostics Market Size, by Application, 2017-2032 (

Companies Mentioned

  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Lucence Health Pte. Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics, Inc.
  • Predicine, Inc.
  • QIAGEN N.V.
  • Sysmex Inostics GmbH
  • Thermo Fisher Scientific Inc.

Related Topics

Related Reports

Circulating Tumor Cell Market - Global Forecast 2026-2032 - Product Image

Circulating Tumor Cell Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Tumor Marker ELISA Kit Market - Global Forecast 2026-2032 - Product Image

Tumor Marker ELISA Kit Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Rare Biomarkers Specimen Collection and Stabilization - Global Strategic Business Report - Product Image

Rare Biomarkers Specimen Collection and Stabilization - Global Strategic Business Report

  • Report
  • 132 Pages
  • Global
From
Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Circulating Tumor DNA (CtDNA) Methylation Market Report 2026 - Product Image

Circulating Tumor DNA (CtDNA) Methylation Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.